Intelligent Bio Solutions Inc. Announces Reverse Stock Split GlobeNewswire
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on INBS
    Intelligent Bio Solutions to Participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025
    8:31a ET November 20 '25 Newsfile Corp

    New York, New York--(Newsfile Corp. - November 20, 2025) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida.

    Conference DetailsDate: December 2-3, 2025Location: Florida Atlantic University, Boca Raton, FL Presentation Date and Time: Wednesday, December 3, 2025, 11:00 a.m. Eastern TimePresentation Location: Presentation Room 2

    A webcast recording of INBS's presentation will be available the following day on INBS's investor relations website, as well as Noble's website and on Channelchek, for 90 days after the event.

    Interested investors can register to attend here using the discount code INBSNOBLECON.

    For more information about the conference, or to schedule a one-on-one meeting with the INBS management team, please contact your Noble Capital Markets representative or email KCSA Strategic Communications at INBS@ksca.com.

    About Intelligent Bio Solutions Inc.  

    Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.  

    For more information, visit https://ibs.inc/

    Company Contact 

    Intelligent Bio Solutions Inc.   info@ibs.inc    LinkedIn | Twitter  

    Investor & Media Contact 

    Valter Pinto, Managing Director   KCSA Strategic Communications   PH: (212) 896-1254   INBS@kcsa.com 

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275270

    COMTEX_470392428/2523/2025-11-20T08:31:39

    Intelligent Bio Solutions to Participate in Noble Capital Markets' 21...
    8:31a ET November 20 '25 Newsfile Corp
    Intelligent Bio Solutions to Participate in Noble Capital Markets' 21...
    8:30a ET November 20 '25 GlobeNewswire
    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial...
    8:30a ET November 12 '25 GlobeNewswire
    Intelligent Bio Solutions Expects to Report Record Fiscal First Quart...
    8:30a ET November 4 '25 GlobeNewswire
    Intelligent Bio Solutions Secures Major UK Contract with Multinationa...
    8:30a ET October 23 '25 GlobeNewswire

    Market data provided by News provided by